Visit the Website for Patients 
Français
Subscribe to our newsletter!
Follow the latest news from CATALIS and Clinical Trials Quebec
Approval Performances
Galaxies 202
Head and Neck Cancer Phase II
- 8.8 weeks
- 1st site activated worldwide
SIRIUS-SLE1
Lupus Phase III
- 7 weeks
- 1st site activated worldwide and second patient enrolled globally
1501-001
Advanced Solid Tumours Phase I
- 7.1 weeks
- 1st site activated worldwide and Canadian FPI
ProHer
Breast Cancer Phase IIIb
- 10.6 weeks
- 1st site activated worldwide
ProHer
Breast Cancer Phase IIIb
- 25 weeks
TCD 17240
Advanced Solid Tumours Phase I/II
- 16.1 weeks
- Canadian regulatory delay 1st site activated worldwide and Canadian FPI
VICTORION-2
Cardiology Phase III
- 7.7 weeks
- 1st site activated worldwide
VICTORION-2
Cardiology Phase III
- 8 weeks
- 2nd site activated worldwide
VICTORION-2
Cardiology Phase III
- 8.7 weeks
- 3rd site activated worldwide and FPI globally
VICTORION-2
Cardiology Phase III
- 9.9 weeks
- 5th site activated worldwide
1434-0017
Chronic Kidney Disease (CKD) Phase III
- 10 weeks
- 1st site activated worldwide
20230191
Cardiology and vascular diseases Phase III
- 8.6 weeks
224035 (NERT)
Solid Tumors Phase I/II
- 10.4 weeks
CEREN-3
ORL Phase III
- 10.4 weeks
- 1st site activated in Canada and Canadian FPI
CHTT227A12301
Huntington's Disease (Neurology) Phase III
- 8 weeks
- 2nd site activated worldwide and 1st site activated in Canada
CHTT227A12301
Huntington's Disease (Neurology) Phase III
- 9.6 weeks
EFC17905
Hemophilia Phase III
- 10.4 weeks
- 1st site activated in Canada